The quest for a new treatment for dry eye disease has hit another roadblock. Aldeyra Therapeutics’ experimental eye drop, reproxalap, has been rejected by the U.S. Food and Drug Administration (FDA) for the third time in three years, casting doubt on its future and impacting a potential collaboration with pharmaceutical giant AbbVie. The FDA’s decision, announced Tuesday, centers on inconsistencies in clinical trial data and a lack of conclusive evidence supporting the drug’s effectiveness. This latest setback underscores the challenges in developing novel therapies for this common, yet often debilitating, condition.
Dry eye disease affects millions worldwide, causing discomfort, vision disturbances, and reduced quality of life. Current treatments often provide only temporary relief, highlighting the need for more effective and long-lasting solutions. Aldeyra’s approach with reproxalap aimed to address the underlying inflammation associated with dry eye by targeting reactive aldehyde species (RASP), molecules produced by the body in response to injury or infection. The drug is designed to neutralize these RASP, potentially reducing inflammation and alleviating symptoms. But, the FDA has repeatedly questioned whether the clinical trials adequately demonstrate this effect.
The FDA’s latest complete response letter, a formal communication outlining the reasons for non-approval, cited “inconsistency of study results” as a primary concern. According to Aldeyra, the agency stated that the “totality of evidence from the completed clinical trials does not support the effectiveness of the product.” This follows previous rejections in 2023 and April 2024, each prompting Aldeyra to conduct additional trials and resubmit its application. The ongoing struggle to gain FDA approval highlights the rigorous standards required for new drug approvals and the complexities of demonstrating efficacy in clinical trials.
A History of Rejections and Extended Reviews
Aldeyra’s journey with reproxalap began with an initial FDA rejection in 2023. The agency requested at least one additional clinical trial to further evaluate the drug’s effectiveness. Aldeyra responded by conducting two “chamber trials,” designed to simulate dry eye exacerbations in a controlled environment. These trials compared reproxalap to a placebo. A 2024 resubmission focused on results from one chamber trial, which showed a reduction in patient-reported eye discomfort. However, the FDA again rejected the application, stating that the data did not demonstrate efficacy in a well-controlled study. The complete response letter from April 2024 detailed these concerns.
Further complicating matters, a second chamber trial also reported a reduction in patient-reported eye discomfort. Reproxalap was also evaluated in a six-week “field trial,” where participants used the drug or a placebo in real-world conditions and reported their symptoms weekly. While the field trial did not achieve statistical significance, Aldeyra maintained that the results indicated some activity. Despite this, the FDA requested the field trial data before completing its review, leading to a three-month extension of the target decision date, as announced in December 2025. This extension signaled the FDA’s continued scrutiny of the data.
What the FDA Wants and Aldeyra’s Next Steps
In its latest communication, the FDA has not called for additional clinical trials, but has recommended that Aldeyra explore the reasons for the failures in certain trials. The agency also suggested identifying specific patient populations or conditions where reproxalap might prove effective. This suggests the FDA isn’t entirely dismissing the drug, but requires a more targeted understanding of its potential benefits. Aldeyra stated it will seek a meeting with the FDA to gain clarity on the requirements for approval, but has no current plans to conduct further clinical testing.
The implications of this rejection extend beyond Aldeyra. AbbVie holds an exclusive option to collaborate on the commercialization of reproxalap, a deal that could be worth up to $300 million. AbbVie initially invested $1 million in 2023 to secure this option and added another $5 million to extend the exercise period. If AbbVie chooses to exercise its option, it would pay Aldeyra $100 million, minus the previous investments, with the potential for further milestone payments. The commercialization agreement would involve a 60/40 profit split in the U.S., with AbbVie receiving the larger share, and royalties for AbbVie’s sales outside the U.S. The future of this collaboration now hangs in the balance, dependent on Aldeyra’s ability to address the FDA’s concerns.
Financial Implications and the Future of Aldeyra
As of the complete of 2025, Aldeyra reported a cash position of $70 million, which the company estimates will fund operations into 2028. This financial cushion provides some runway for Aldeyra to navigate this challenging situation. However, the lack of a clear path to approval for reproxalap raises questions about the company’s long-term prospects. The development of reproxalap has been a central focus for Aldeyra, and its failure could significantly impact the company’s future strategy.
Aldeyra CEO Todd Brady expressed disappointment with the FDA’s decision but remains optimistic. In a prepared statement, Brady stated, “To the thousands of American and Canadian patients who participated in our clinical trials and to the tens of millions of patients with dry eye disease worldwide, I seek to assure you that we will work with urgency to support the FDA in enabling market access to what is, to our knowledge, the only drug with clinical activity within minutes of administration in patients with dry eye disease, a condition that is today treated with medications that require weeks or months of treatment to achieve even modest improvement.” This statement underscores Aldeyra’s belief in the potential of reproxalap, despite the repeated setbacks.
Understanding Reactive Aldehyde Species (RASP) and Dry Eye Disease
Aldeyra’s approach to treating dry eye disease is based on the understanding of the role of reactive aldehyde species (RASP) in inflammation. RASP are molecules produced by the body in response to various triggers, including infection, injury, and oxidative stress. Elevated levels of RASP contribute to inflammation, which is a key factor in the development and progression of dry eye disease. Reproxalap is designed to bind to and neutralize these RASP, thereby reducing inflammation and alleviating symptoms. This mechanism of action differentiates reproxalap from many existing dry eye treatments, which primarily focus on symptom relief rather than addressing the underlying inflammatory process.
Dry eye disease is a common condition affecting millions of people worldwide. Symptoms can range from mild discomfort to severe pain and vision impairment. The condition can be caused by a variety of factors, including aging, hormonal changes, environmental factors, and certain medical conditions. Current treatments include artificial tears, prescription eye drops, and in some cases, surgery. However, many patients find that these treatments provide only temporary relief, highlighting the need for more effective and targeted therapies.
The FDA’s continued scrutiny of reproxalap underscores the challenges in developing new treatments for complex conditions like dry eye disease. Demonstrating efficacy in clinical trials requires rigorous scientific evidence and a thorough understanding of the underlying disease mechanisms. The FDA’s decision serves as a reminder of the importance of robust clinical trial design and the need for clear and consistent data to support drug approvals.
Key Takeaways:
- Aldeyra Therapeutics’ reproxalap has received its third rejection from the FDA for the treatment of dry eye disease.
- The FDA cited inconsistencies in clinical trial results and a lack of conclusive evidence supporting the drug’s effectiveness.
- AbbVie’s potential collaboration with Aldeyra, valued at up to $300 million, is now uncertain.
- Aldeyra plans to meet with the FDA to discuss the requirements for approval and does not currently plan additional clinical trials.
The next step for Aldeyra is to schedule and conduct a meeting with the FDA to discuss the agency’s concerns and explore potential pathways to approval. The outcome of this meeting will be crucial in determining the future of reproxalap and Aldeyra’s overall strategy. Readers interested in following this story can find updates on the Aldeyra Therapeutics Investor Relations website. We encourage you to share this article and join the conversation in the comments below.